全文获取类型
收费全文 | 34110篇 |
免费 | 3735篇 |
国内免费 | 2382篇 |
专业分类
耳鼻咽喉 | 289篇 |
儿科学 | 474篇 |
妇产科学 | 387篇 |
基础医学 | 3831篇 |
口腔科学 | 632篇 |
临床医学 | 4703篇 |
内科学 | 4933篇 |
皮肤病学 | 310篇 |
神经病学 | 1624篇 |
特种医学 | 1448篇 |
外国民族医学 | 14篇 |
外科学 | 3754篇 |
综合类 | 5861篇 |
现状与发展 | 9篇 |
一般理论 | 3篇 |
预防医学 | 2204篇 |
眼科学 | 781篇 |
药学 | 3780篇 |
48篇 | |
中国医学 | 2099篇 |
肿瘤学 | 3043篇 |
出版年
2024年 | 148篇 |
2023年 | 627篇 |
2022年 | 1493篇 |
2021年 | 2019篇 |
2020年 | 1553篇 |
2019年 | 1242篇 |
2018年 | 1302篇 |
2017年 | 1217篇 |
2016年 | 1181篇 |
2015年 | 1676篇 |
2014年 | 1986篇 |
2013年 | 1802篇 |
2012年 | 2336篇 |
2011年 | 2673篇 |
2010年 | 1701篇 |
2009年 | 1324篇 |
2008年 | 1646篇 |
2007年 | 1704篇 |
2006年 | 1612篇 |
2005年 | 1537篇 |
2004年 | 1155篇 |
2003年 | 1172篇 |
2002年 | 1040篇 |
2001年 | 885篇 |
2000年 | 818篇 |
1999年 | 765篇 |
1998年 | 443篇 |
1997年 | 508篇 |
1996年 | 340篇 |
1995年 | 302篇 |
1994年 | 233篇 |
1993年 | 191篇 |
1992年 | 233篇 |
1991年 | 214篇 |
1990年 | 183篇 |
1989年 | 165篇 |
1988年 | 134篇 |
1987年 | 135篇 |
1986年 | 115篇 |
1985年 | 76篇 |
1984年 | 50篇 |
1983年 | 28篇 |
1982年 | 16篇 |
1981年 | 17篇 |
1980年 | 25篇 |
1979年 | 45篇 |
1978年 | 22篇 |
1976年 | 12篇 |
1975年 | 18篇 |
1974年 | 20篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Background: Breast cancer (BC) is the most common malignant tumor in women, and its morbidity and mortality are
increasing each year, due to the lack of specific clinical symptoms in the early stage of BC, and the lack of diagnostic
methods for early breast cancer. Therefore, identifying an effective diagnostic method for early BC has become urgent.
Materials and Methods: Breast lesions with a histological diagnosis that were examined by ultrasonic elastography
(UE) in our department from June 2020 to December 2021 were reviewed. qRT-PCR was performed to measure
the expression levels of miR-144-5p and miR-26b-5p in the plasma of patients with BC. The receiver operating characteristics (ROC) curve and area under the curve (AUC) were used to investigate the potential diagnostic value of miR-
144-5p, miR-26b-5p and the elastographic score in BC. Results: The ultrasonic elastography score(UES) was found to
be significantly upregulated in BC compared with that in benign breast lesions, and the AUC, sensitivity and specificity
were 0.809, 0.717 and 0.806 for distinguishing BC from benign breast lesions, respectively. miR-144-5p and miR-26b-
5p were found to be upregulated in the plasma of BC patients, and miR-144-5p+miR-26b-5p had 0.781 sensitivity and
0.780 specificity for the diagnosis of BC. Furthermore, we found that the diagnostic performance of miR-144-5p and
miR-26b-5p combined with UES for BC had 0.913 sensitivity and 0.890 specificity. Conclusions: The combination of
plasma miR-144-5p, miR-26b-5p and UES has a very high clinical application value for the early detection of BC. 相似文献
2.
3.
Qiangsheng He Chongfei Huang Xiwen Qin Yuanyuan Yu Di Tang Junjie Huang Zi Chong Kuo Yuyao Ling Deli Mao Bin Xia Wenjing Li Kuiqing Lu Man Yang Yulong He Wenbo Meng Jinqiu Yuan Yihang Pan 《International journal of cancer. Journal international du cancer》2023,153(5):942-949
Recent epidemiological studies suggested that proton pump inhibitor (PPI) use was associated with an increased risk of biliary tract cancer (BTC), however, confounders were not adequately controlled. Our study aimed to evaluate PPI use and subsequent risk of BTC and its subtypes in three well-established cohorts. We conducted a pooled analysis of the subjects free of cancers in UK Biobank (n = 463 643), Nurses' Health Study (NHS, n = 80 235) and NHS II (n = 95 869). Propensity score weighted Cox models were used to estimate marginal HRs of PPIs use on BTC risk, accounting for potential confounders. We documented 284 BTC cases in UK Biobank (median follow-up: 7.6 years), and 91 cases in NHS and NHS II cohorts (median follow-up: 15.8 years). In UK biobank, PPI users had a 96% higher risk of BTC compared to nonusers in crude model (HR 1.96, 95% CI 1.44-2.66), but the effect was attenuated to null after adjusting for potential confounders (HR 0.95, 95% CI 0.60-1.49). PPI use was not associated with risk of BTC in the pooled analysis of three cohorts (HR 0.93, 95% CI 0.60-1.43). We also observed no associations between PPI use with risk of intrahepatic (HR 1.00, 95% CI 0.49-2.04), extrahepatic bile duct (HR 1.09, 95% CI 0.52-2.27) and gallbladder cancers (HR 0.66, 95% CI 0.26-1.66) in UK Biobank. In summary, regular use of PPIs was not associated with the risk of BTC and its subtypes. 相似文献
4.
5.
Xiumei Jiang Xiaowei Zhang Patrick Gray Jiwen Zheng Timothy R. Croley Peter P. Fu 《journal of environmental science and health part c-environmental carcinogenesis & ecotoxicology reviews》2019,37(2):116-131
Gold nanoparticles (Au NPs) hold great promise in food, industrial and biomedical applications due to their unique physicochemical properties. However, influences of the gastrointestinal tract (GIT), a likely route for Au NPs administration, on the physicochemical properties of Au NPs has been rarely evaluated. Here, we investigated the influence of GIT fluids on the physicochemical properties of Au NPs (5, 50, and 100?nm) and their implications on intestinal epithelial permeability in vitro. Au NPs aggregated in fasted gastric fluids and generated hydroxyl radicals in the presence of H2O2. Cell studies showed that GIT fluids incubation of Au NPs affected the cellular uptake of Au NPs but did not induce cytotoxicity or disturb the intestinal epithelial permeability. 相似文献
6.
7.
Simeprevir added to peginterferon and ribavirin lessens time with fatigue,depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies
下载免费PDF全文
![点击此处可从《Journal of viral hepatitis》网站下载免费的PDF全文](/ch/ext_images/free.gif)
J. Scott L. Gilles M. Fu E. Brohan C. Panter R. Arbuckle W. Jessner M. Beumont 《Journal of viral hepatitis》2015,22(8):639-650
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (n = 768 SMV/PR, n = 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity. 相似文献
8.
9.
10.